Four-year Experience of Growth Hormone Treatment in Children with Non-endocrine Short Stature
スポンサーリンク
概要
- 論文の詳細を見る
Fifty-three children with non-endocrine short stature (NESS) were treated with recombinant human growth hormone (GH) for four years. GH treatment significantly increased height velocity, height SD score (SDS), and height velocity SDS for chronological age (CA) in NESS. The mean height velocity was increased by GH treatment from 4.4cm/year to 7.2cm/year in the first year, 6.3cm/year in the second year, 5.7cm/year in the third year and 5.4cm/year in the fourth year; the mean height SDS from -3.15 SD to -2.70 SD in the first year, -2.49 SD in the second year, -2.40 SD in the third year and -2.34 SD in the fourth year. However, evaluated in terms of the height SDS for bone age, no significant improvement in the effect was observed.Twenty-seven children developed puberty during the four-year GH treatment. The height at the onset of puberty was shorter than that of normal children. The earlier GH treatment started, the younger age and the shorter height the patients entered puberty. Since it is known that the height at onset of puberty correlates well with the final height, it is probable that the patients who developed puberty at short stature in this study will remain short as adults. The effect of GH treatment in children with NESS should be carefully evaluated by conducting a long-term follow-up.
- 日本小児内分泌学会の論文
日本小児内分泌学会 | 論文
- 43 Common origin of the Q258X mutation in StAR gene responsible for congenital aderenal lipoid hyperplasia in Japanese
- Recent Change in the Annual Incidence of Childhood Type 2 Diabetes in the Tokyo Metropolitan Area
- A Case of Acute Lymphoblastic Leukemia with Prader-Willi Syndrome during Growth Hormone Therapy
- Characteristics of a Fulminant Onset Form of Idiopathic Type 1 Diabetes Mellitus in Japanese Children
- Different Skeletal Phenotypes in a Mother and Two Daughters with Short Stature Homeobox-Containing Haploinsufficiency